Compare Cassava Sciences Inc (FLNA) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs GeneDx Holdings Corp — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while GeneDx Holdings Corp trades at $82.67 (market cap $2.44B). The key difference: GeneDx Holdings Corp is far larger — about 51.1× Cassava Sciences Inc's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | WGS | |
|---|---|---|
Market Cap | $47.75M | $2.44B |
Sector | Health | Technology |
52-Week High | $4.64 | $167.51 |
52-Week Low | $0.87 | $34.51 |
Enterprise Value | -$34.93M | $2.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
